Abstract Background and aims Cognitive disorders (CD) is a significant cause of disability and limitation of capabilities in people who have suffered a stroke. Methods 93 patients aged 54.7 ± 14.8 years who had suffered a stroke were examined. All patients underwent neurological examination, neuropsychological testing, and neuroimaging. Depending on the severity and prevalence of CD, patients were divided into groups: group 1 (n=21) - with focal disorders, group 2 (n=25) - with multiple CD, without dementia; group 3 (n=27) - with post-stroke dementia; group 4 (n=20) - control. Results In each group, patients with early and late CD were identified. The main causes of CD in group 1 were patients with ischemic 65% and 35% with hemorrhagic strokes, in group 2 – ischemic 39%, massive hemorrhagic 61%, in group 3 – multiple lacunar infarctions 46%, hemorrhages 54%. Patients were prescribed treatment with citicoline at a dose of 1000 mg per day, group 2 was added amantadine at a dose of 100 mg twice a day, group 3 – amantadine 100 mg twice a day and donepezil at a dose of 5 mg per day. The course of treatment was 3 months. During the treatment, changes occurred: on the Mokka scale in group 1 21.7±1.3 versus 19.2±1.8 before treatment; group 2 - 24.2±1.1 vs. 18.2±0.9 before treatment (p0.05); group 3 - 23.3±0.6 vs. 16.7±0.5 (p0.05), respectively. Conclusions The risk of developing post-stroke CD does not depend on the nature and severity of the stroke; citicoline, amantadine, and cholinesterase inhibitors in treatment regimens have a positive effect on CD. Conflict of interest KateynaTarianyk: nothing to disclose; Nazarii Kalynovych: nothing to disclose
Tarianyk et al. (Fri,) studied this question.